Abstract:Abstract 2730 Introduction: Recently, L-asparaginase-based combination chemotherapy was found to be effective in salvage treatment in patients with relapsed or refractory extranodal NK/T-cell lymphoma, nasal type. To explore the single-agent activity of L-asparaginase, we conducted a single-institute, prospective phase II study. Methods: Patients with relapsed or refractory extranodal NK/T-cell lymphoma, nasal type were eligible for enrollment regardless of prior treatment. L-asparaginase monotherapy (6000 U/m2 on days 1 to 7) was administered as the protocol treatment and repeated every 3 weeks for at most 8 cycles. For responding patients, the decision to proceed with hematopoietic stem-cell transplantation was made at the discretion of treating physicians. The primary endpoint was the best objective response after L-asparaginase. Results: A total of 40 patients were enrolled and treated with L-asparaginase for a median of 5 cycles (range, 1 – 8). The patient characteristics were shown in Table 1. Half of the patients had stage IV disease at enrollment and the vast majority (18 patients) presented with disseminated cutaneous and soft-tissue involvement. Thirty-seven patients (92.5%) had prior exposure to systemic chemotherapy and 14 of them (37.8%) received more than 1 line. The overall response rate was 82.5%. The complete response (CR) and partial response (PR) rates were 40% and 42.5%, respectively. The incidence of adverse events was shown in Table 2. In short, anemia, neutropenia, hypoalbuminemia, nausea and liver-related disorders were common toxicities, which were usually mild and manageable. No grade 4 adverse events and treatment-related mortality were observed. Five patients (12.5%) developed allergic reaction to L-asparaginase and 3 of them had to withdraw from the study since L-asparaginase re-challenge with prophylactic antiallergic agents was unsuccessful. After a median follow-up time of 31.6 months (range, 21.9 – 41.3), the median progression-free survival (PFS) was 12.8 months and median overall survival (OS) was not reached. Response status (CR, PR or no response) after L-asparaginase had a significant impact on either PFS (Figure 1) or OS (Figure 2). Moreover, its prognostic value was confirmed in the multivariate analysis. Conclusions: L-asparaginase demonstrated a high single-agent activity in salvage setting for patients with extranodal NK/T-cell lymphoma, nasal type. The first-line L-asparaginase-containing chemotherapy regimen warrants urgent investigation. Disclosures: Off Label Use: L-asparaginase, which was used in our study for NK/T-cell lymphoma, is approved to treat acute lymphocytic leukemia by US and Chinese FDA.

[The Efficacy of L-asparaginase in the Treatment of Refractory Midline Peripheral T-cell Lymphoma].

[A Clinical Observation of Treatment of Peripheral T-cell Lymphoma with L-asparaginase-containing Combination Chemotherapy].

Therapeutic Efficacy of L-asparaginase in the Treatment of Refractory Midfacial Peripheral T-cell Non-Hodgkin’s Lymphoma

Clinical Analysis And Prognostic Significance Of L-Asparaginase Containing Multidrug Chemotherapy Regimen In Incipient Peripheral T-Cell Lymphoma

[Therapeutic Efficacy of VICP+L-ASP/TKI on Adult Patients with B-ALL].

L-Asparaginase in the Treatment of Refractory and Relapsed Extranodal NK/T-cell Lymphoma, Nasal Type

Midline NK/T-cell Lymphoma Nasal-Type: Treatment Outcome, the Effect Ofl-Asparaginase Based Regimen, and Prognostic Factors

L-Asparaginase Monotherapy in Patients with Relapsed or Refractory Extranodal NK/T-Cell Lymphoma, Nasal Type: Results of A Phase II Study.

Long-Term Efficacy Of Low-Dose All-Trans Retinoic Acid Plus Minimal Chemotherapy Induction Followed By The Addition Of Intravenous Arsenic Trioxide Post-Remission Therapy In Newly Diagnosed Acute Promyelocytic Leukaemia

Bortezomib-based therapy for transplant-ineligible East Asian patients with newly diagnosed mantle-cell lymphoma.

Long-Term Efficacy of Low-Dose All-Trans Retinoic Acid Plus Individually Adapted Chemotherapy Induction Followed by Arsenic Trioxide Based Post-Remission Therapy in Adults with Newly Diagnosed Acute Promyelocytic Leukemia

Safety and adverse event profiling of pegylated L-asparaginase combined chemotherapy in the treatment of lymphoma

Comparison Analysis of First-Line Asparaginase- Versus Non-Asparaginase-based Regimens for Early-Stage Extranodal NK/T-cell Lymphoma.

PEG-asparaginase in BFM-90 Regimen Improves Outcomes in Adults with Newly Diagnosed Lymphoblastic Lymphoma

Acrylic microspheres in vivo VI: antitumor effect of microparticles with immobilized L-asparaginase against 6C3HED lymphoma

[Retrospective Analyses of CHOPE Plus L-asparaginase Regimen in Treatment of T-cell Lymphoma].

Clinical Efficacy And Toxicity Of Peg-Asparaginase In Patients With Solid Tumor And All: A Meta-Analysis

First-line l-asparaginase-based chemotherapy plus radiotherapy is active in stage i/ii extranodal nk/t-cell lymphoma: results from peking university cancer hospital

[Progress in therapy with L-asparaginase]

Successful treatment with L-asparaginase-based regimen for primary pulmonary NK/T cell lymphoma: a case report and review of the literature

A prospective phase II study of L-asparaginase- CHOP plus radiation in newly diagnosed extranodal NK/T-cell lymphoma, nasal type